|
Human Brain Proteins with Evidence Consistent with Causality of Alzheimer’s and Depression
Application
Research and therapeutic targets for Alzheimer’s disease, depression, and other neurological conditions mediated by protein expression in the brain.
Key Benefits
These findings can be utilized as a research tool to better understand the genetic basis of Alzheimer’s disease.
Can also be utilized to develop therapeutics for...
Published: 12/20/2023
Contributor(s): Aliza Wingo, Thomas Wingo, Yue Liu, Allan Levey, Nicholas Seyfried, Duc Duong
|
|
EF-Tu Targeting Antibody for Infection Treatment
Application
Therapeutic monoclonal antibodies directed to Elongation Factor-Tu (EF-Tu) for the treatment of infections.
Key Benefits
An antibody that targets the protein EF-Tu, which is present on many types of bacteria involved in life-threatening infections.
A research-grade antibody has been developed with animal data showing the ability to...
Published: 10/13/2023
Contributor(s): Joanna Goldberg, Dina Moustafa
|
|
A Predictive Marker and Treatment to Sensitize Multiple Myeloma Patients to Venetoclax (ABT-199)
Application
A marker that predicts Venetoclax (ABT-199) sensitivity that can also be targeted with a drug to help multiple myeloma patients.
Key Benefits
Marker that predicts if venetoclax will be an effective treatment in multiple myeloma patients.
A drug that targets venetoclax resistant multiple myeloma cells to improve treatment in patients.
Market...
Published: 7/28/2023
Contributor(s): Malathy (mala) Shanmugam, Richa Bajpai
|
|
KRAS Mutant Protein-Protein Interaction Targets and Inhibitors for Cancer Therapy
Application
Immunotherapeutic agent and biosensor for KRASG12V mutation in tumor cells.
Key Benefits
First in class, targeted immunotherapy for patients presented with KRASG12V mutation.
Attenuates immune suppression associated with KRASG12V-positive cancers.
Market Summary
The KRASG12V mutation, representing 85% of all cancer mutations, is...
Published: 4/11/2024
Contributor(s): Haian Fu, Cong Tang, Xiulei Mo
|
|
Combination Therapy for Increasing Venetoclax Sensitivity in Multiple Myeloma
Application
Marker and co-therapy that inhibits succinate dehydrogenase to increase patient response to venetoclax.
Key Benefits
Co-therapy increases MM sensitivity to venetoclax treatment.
Identifies patients who will respond to venetoclax therapy.
Market Summary
Multiple Myeloma (MM) is a cancer of plasma cells responsible for making antibody...
Published: 12/1/2023
Contributor(s): Malathy (mala) Shanmugam, Richa Bajpai
|
|
Peptide Therapeutic for Acute Respiratory Distress Syndrome
Application
Anti-claudin 5 peptide to improve lung barrier function for the treatment of alcohol-induced acute respiratory distress syndrome (ARDS).
Key Benefits
New target for treating ARDS.
Small inhibitory peptide to specifically target claudin-5.
Market Summary
Acute respiratory distress syndrome (ARDS) is a rapidly progressive disease...
Published: 11/27/2023
Contributor(s): Michael Koval, Barbara Schlingmann-Molina
|
|
Therapeutic Target for Hepatic Fibrosis
ApplicationPeriostin as a therapeutic target for liver disease.Key BenefitsNew therapeutic target for preventing fibrosis from entering cirrhosis stage.Therapeutic target may be used for identifying new therapy for fibrosis.Market SummaryCirrhosis is a condition in which the liver is unable to function normally due to chronic, or long lasting, injury....
Published: 11/27/2023
Contributor(s): Frank Anania, Pradeep Kumar
|
|
Targeting Peptide Improves Accurate Myocarditis Imaging and Diagnosis
ApplicationTargeting peptide molecule for image-based diagnosis of myocarditis.Key BenefitsEnables noninvasive diagnosis of myocarditis.Targets and binds to biomarker of myocarditis.Market SummaryMyocarditis is an inflammation of the heart muscle (myocardium). Myocarditis can affect your heart muscle and your heart's electrical system, reducing the...
Published: 11/6/2023
Contributor(s): Michael E. Davis, Mario Martinez
|
|
Nox cDNA and Enzymes for Drug Discovery, for Diagnostics, and as Research Tools
Application
Target for drug discovery, gene therapy and to create a diagnostic tool relevant to conditions involving inappropriate cell proliferation.
Technical Summary
Reactive oxygen species (ROS) include superoxide and hydrogen peroxide. ROS are increasingly being recognized as playing a central role in diverse physiologic and pathologic processes....
Published: 7/28/2023
Contributor(s): John David Lambeth, Guang Cheng
|
|
Targeted Drug Development for Abnormal Proliferation
Applications
Target for drug development for diseases involving abnormal proliferation of cells, including psoriasis (hyperproliferation of skin cells) and benign prostatic hypertrophy.
Technical Summary
Reactive oxygen intermediates (ROI) are generated during an oxidative process that occurs in many cell types. The result of generating reactive...
Published: 11/27/2023
Contributor(s): John David Lambeth, Bernard Lassegue, Kathy Griendling, Rebecca Arnold, Guang Cheng
|